PD-L1:B7-1[Biotinylated] Inhibitor Screening Assay Kit

Catalog #
72026
$1,215 *
Size: 96 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The PD-L1:B7-1[Biotinylated] Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of the PD-L1:B7-1 interaction. The key to this kit is the high sensitivity of detection of biotin-labeled B7-1 by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, PD-L1 is coated on a 96-well plate. Next, B7-1-biotin is incubated with PD-L1 on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a chemiluminescence reader.

Need us to run inhibitor screens or profile your compounds against PD-L1:B7-1 [Biotinylated]? Check out our Immunotherapy Biochemical Screening Services.

Synonyms
Programmed Cell Death 1 Ligand 1, CD274, B7 homolog 1 (B7-H1), CD80, CTLA-4 Counter-Receptor B7.1 , activity assay kit
Product Info
Storage and Usage
Citations
Assay Kit Format
Chemiluminescent
Supplied As
This kit comes in a convenient 96-well format, with biotin-labeled B7-1 (CD80), purified PD-L1, streptavidin-labeled HRP, and assay buffer for 100 binding reactions.
Format

 

Catalog
Number

Component

Amount

Storage
71104 PD-L1, Fc fusion 25 µg -80°C





Avoid freeze/

thaw cycles!
71114 B7-1 (CD80), Fc fusion, Biotin-labeled 15 µg -80°C
79742 Streptavidin-HRP 10 µl +4°C
79311 3x Immuno Buffer 1 50 ml -20°C
79728 Blocking Buffer 2 50 ml +4°C
79670 ELISA ECL substrate A
(transparent bottle)

6 ml

Room Temp.
ELISA ECL substrate B
(brown bottle)

6 ml

 

Room Temp.

79699 White 96-well microplate 1 +4°C
UniProt #
PD-L1: Q9NZQ7; B7-1: P33681
Background
There have been a number of studies defining a role for PD-L1 in the regulation of immune tolerance and cancer immunity through binding to T cell-expressed PD-1. Interestingly, PD-L1 has also been shown to interact with B7-1, also known as CD80. Like PD- 1:PD-L1 interaction, B7-1:PD-L1 signaling also leads to inhibition of T cell activation, proliferation, and cytokine production, suggesting that this pathway may also serve as a target in cancer immunotherapy and inflammatory diseases.
References
1. Butte, M.J., et al., Immunity. 2007; 27(1): 111-122.
2. Butte, M.J. et al., Mol. Immunol. 2008; 45: 3567-3572.